Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630069 | 0.93 | STING1 (0.81) | STING1CYP3A4 | |
| SCHEMBL28751943 | 0.92 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL21620343 | 0.92 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL20876349 | 0.92 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL29791173 | 0.92 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL19451834 | 0.92 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL22932861 | 0.91 | STING1 (0.87) | STING1CYP3A4 | |
| SCHEMBL21620344 | 0.91 | STING1 (0.87) | STING1CYP3A4 | |
| SCHEMBL23637208 | 0.90 | STING1 (0.78) | STING1CYP3A4 | |
| SCHEMBL25871705 | 0.90 | STING1 (0.95) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| WO-2020010451-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | STING1, MAVS, IRF3 | STING1 1/4885CYP3A4 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.